تقرير
أعرض في EDS

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.

التفاصيل البيبلوغرافية
العنوان: Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
المؤلفون: Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, Phillips AL, Ellingson K, Ferraris MV, LeClair LB, Mathenge C, Yoo YM, Thiese MS, Gerald LB, Solle NS, Jeddy Z, Odame-Bamfo L, Mak J, Hegmann KT, Gerald JK, Ochoa JS, Berry M, Rose S, Lamberte JM, Madhivanan P, Pubillones FA, Rai RP, Dunnigan K, Jones JT, Krupp K, Edwards LJ, Bedrick EJ, Sokol BE, Lowe A, McLeland-Wieser H, Jovel KS, Fleary DE, Khan SM, Poe B, Hollister J, Lopez J, Rivers P, Beitel S, Tyner HL, Naleway AL, Olsho LEW, Caban-Martinez AJ, Burgess JL, Thompson MG, Gaglani M
المصدر: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2022 Mar 18; Vol. 71 (11), pp. 422-428. Date of Electronic Publication: 2022 Mar 18.
نوع المنشور: Technical Report
اللغة: English
بيانات الدورية: Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: Atlanta, GA : U.S. Centers for Disease Control
Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control.
مواضيع طبية MeSH: Vaccine Efficacy*, BNT162 Vaccine/*administration & dosage , BNT162 Vaccine/*therapeutic use , COVID-19/*prevention & control , SARS-CoV-2/*immunology, Adolescent ; Child ; Child, Preschool ; Cohort Studies ; Female ; Humans ; Male ; Prospective Studies ; United States
مستخلص: The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) on May 12, 2021, and for children aged 5-11 years on November 2, 2021 (1-4). Real-world data on vaccine effectiveness (VE) in these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant in the United States in December 2021, early investigations of VE demonstrated a decline in protection against symptomatic infection for adolescents aged 12-15 years and adults* (5). The PROTECT † prospective cohort of 1,364 children and adolescents aged 5-15 years was tested weekly for SARS-CoV-2, irrespective of symptoms, and upon COVID-19-associated illness during July 25, 2021-February 12, 2022. Among unvaccinated participants (i.e., those who had received no COVID-19 vaccine doses) with any laboratory-confirmed SARS-CoV-2 infection, those with B.1.617.2 (Delta) variant infections were more likely to report COVID-19 symptoms (66%) than were those with Omicron infections (49%). Among fully vaccinated children aged 5-11 years, VE against any symptomatic and asymptomatic Omicron infection 14-82 days (the longest interval after dose 2 in this age group) after receipt of dose 2 of the Pfizer-BioNTech vaccine was 31% (95% CI = 9%-48%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. Among adolescents aged 12-15 years, adjusted VE 14-149 days after dose 2 was 87% (95% CI = 49%-97%) against symptomatic and asymptomatic Delta infection and 59% (95% CI = 22%-79%) against Omicron infection. Fully vaccinated participants with Omicron infection spent an average of one half day less sick in bed than did unvaccinated participants with Omicron infection. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Allison L. Naleway reports institutional support from Pfizer for an unrelated study of meningococcal B vaccine safety during pregnancy. Matthew S. Thiese reports grants and personal fees from Reed Group and the American College of Occupational and Environmental Medicine, outside the submitted work. No other potential conflicts of interest were disclosed.
References: N Engl J Med. 2021 Jul 15;385(3):239-250. (PMID: 34043894)
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1761-1765. (PMID: 34968373)
N Engl J Med. 2022 Jan 6;386(1):35-46. (PMID: 34752019)
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):749-752. (PMID: 34014913)
MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1579-1583. (PMID: 34758012)
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):352-358. (PMID: 35239634)
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. (PMID: 35176007)
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500. (PMID: 33793460)
المشرفين على المادة: N38TVC63NU (BNT162 Vaccine)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20220317 Date Completed: 20220324 Latest Revision: 20220401
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8942308
DOI: 10.15585/mmwr.mm7111e1
PMID: 35298453
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-861X
DOI:10.15585/mmwr.mm7111e1